← MDGL: big moves and long-term fundamentals中文

Madrigal Pharmaceuticals: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 3, 2026 · Reflects: 10-K FY2025 and the 10-Q for Q3 2026

Disclosure: one or more of our editors own shares of Madrigal Pharmaceuticals (MDGL) as a long-term investment. Disclosure: one or more of our editors own shares of Arrowhead Pharmaceuticals (ARWR), named on this page, as a long-term investment. This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Nov 3, 2026. Reflects the 10-K FY2025 and the 10-Q for Q3 2026.

Madrigal sells one medicine, Rezdiffra (resmetirom), a once-daily pill for MASH (metabolic dysfunction-associated steatohepatitis), a fatty-liver disease that scars the liver. Madrigal reports one segment, and in 2025 all $958.4M of its revenue (100%) was Rezdiffra net product revenue; it does not split sales by country. In the first nine months of 2026 net product revenue was $1,106.9M, and more than 55,850 patients were on Rezdiffra at Sep 30, 2026. Q3 2026 was its first profitable quarter (net income $55.4M).

  • Rezdiffra is approved for adults with moderate to advanced liver scarring (fibrosis stages F2 to F3) but not cirrhosis.
  • The US approval (March 2024) and the EU approval (August 2025) are both conditional on outcomes data that confirm the clinical benefit; Madrigal expects those data from its MAESTRO-NASH trial in 2028.
  • Madrigal sells mainly to a small number of specialty pharmacies and distributors and pays Roche, which discovered the molecule, a tiered single-digit royalty on net sales.
  • A second Phase 3 trial, MAESTRO-NASH OUTCOMES, tests Rezdiffra in compensated cirrhosis (F4c: advanced liver scarring while the liver still performs its essential functions), with results now expected in late 2027. Madrigal plans a further cirrhosis outcomes trial, MAESTRO-CSPH, to start in the first half of 2027, subject to regulatory discussions.
  • Since mid-2025 Madrigal has licensed other MASH drug candidates, intended for use in combination with Rezdiffra.

Sources: 10-K FY2025 (business, segment note, Roche agreement, trials); 10-Q Q3 2026; Q3 release (patients, trials).

2. Story so far

Last updated Nov 3, 2026. Reflects filings through Nov 3, 2026.

In short: Madrigal’s filings show a development company that funded itself by selling shares, preferred stock and pre-funded warrants, then won US accelerated approval for Rezdiffra in March 2024 and EU conditional approval in August 2025. Net sales reached $958.4M in 2025, the drug’s first full year. From July 2025 Madrigal took on a $350M term loan and spent about $255M in upfront payments licensing pipeline drugs from CSPC, Pfizer, Ribocure and Arrowhead. In Q3 2026 it reported its first quarterly profit.

Date Milestone Source
Dec 23, 2022 Sells 44,444 common shares and 400,000 Series B convertible preferred shares at $225 to existing investors ($100.0M gross), after $159.1M of at-the-market share sales (shares sold through an agent at prevailing market prices) that month 10-K FY2022, note 7
Oct 3, 2023 Closes a $500.0M offering: 1.25M common shares at $151.69 and pre-funded warrants (warrants with a $0.0001 exercise price) for 2.05M shares 8-K; 10-K FY2023
Mar 14, 2024 ★ FDA grants accelerated approval of Rezdiffra for F2–F3 MASH, the first approved MASH drug; US launch in April 2024 8-K; 10-K FY2025
Mar 21, 2024 Closes an offering at $260 a share: 750,000 common shares and pre-funded warrants for 1.56M shares, plus 346,153 option shares on Apr 2 8-K; 10-K FY2024
Oct 2024 Completes enrolment of MAESTRO-NASH OUTCOMES in compensated cirrhosis (845 patients) 10-K FY2025
Jul 17, 2025 Signs a Blue Owl credit facility of up to $500M; draws $350M and repays $121.7M owed to Hercules 8-K; 10-Q Q2 2026, note 8
Jul 30, 2025 ★ Licenses MGL-2086, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, from CSPC: $120.0M upfront (paid Oct 2025), up to $2.0B in milestones. It is the first of four pipeline licences in ten months 8-K; 10-Q Q2 2026
Aug 2025 ★ European Commission grants conditional approval; German launch in September 2025 10-K FY2025
Dec 2025 Licenses ervogastat (an oral DGAT-2 inhibitor, which blocks a step in triglyceride production) and two early assets from Pfizer: $50.0M upfront, up to $70.0M in ervogastat development and regulatory milestones 10-Q Q2 2026
Jan 2026 Amends the Roche agreement: Madrigal controls patent term extensions for Rezdiffra; in return the Roche royalty is not reduced until certain extensions expire 8-K, Jan 30; 10-Q Q2 2026
Feb 19, 2026 2025 results: net sales $958.4M (Q4 $321.1M); more than 36,250 patients on Rezdiffra at year-end Q4 release
Feb 2026 Licenses six small interfering RNA (siRNA) gene-silencing programmes from Ribocure: $60.0M upfront, up to $4.4B in milestones 10-Q Q2 2026
May 2026 Licenses MGL-0795 (an siRNA targeting PNPLA3, a gene linked to MASH) from Arrowhead: $25.0M upfront, up to $975.0M in milestones. The Q1 10-Q also revises past loss per share to count the preferred stock and pre-funded warrants (2025: −$12.85 → −$10.15) 10-Q Q1 2026; 10-Q Q2 2026
Jul 30, 2026 Q2 net sales $364.3M (+71% year on year); more than 49,000 patients at Jun 30; three new US patents, including one for F4c (expected protection into 2042) Q2 release
Oct 28, 2026 Start of our coverage: this Long View WhyMyStockMoved
Nov 3, 2026 ★ Q3 net sales $431.3M (+50% year on year) and first quarterly profit (net income $55.4M); more than 55,850 patients; MAESTRO-NASH OUTCOMES results now expected in late 2027; plans a second cirrhosis outcomes trial, MAESTRO-CSPH Q3 release

3. Latest quarter: did the story change?

Last updated Nov 3, 2026. Reflects Q3 2026 (10-Q filed Nov 3, 2026), the Q3 release and call.

Bottom line: In Q3 2026 net sales rose 18% from Q2, patients on therapy rose again and Madrigal reported its first quarterly profit; free cash flow (operating cash flow less capital spending) was about +$116.6M (our calculation). It still gives no numeric sales guidance, and its CFO said it “may dip in and out of profitability” in the near term (Q3 release; call transcript).

Driver Last quarter → this quarter Management: before → now Signal
Net sales Q2 $364.3M → Q3 $431.3M (+18% on Q2; +50% year on year) No numeric sales guidance (Jul 30) → still none; the CFO feels good about “the consensus growth rate” from Q3 to Q4 (Nov 3) Better
Patients on Rezdiffra More than 49,000 (Jun 30) → more than 55,850 (Sep 30) “Steadily add patients” (CEO, Jul 30) → the same aim (CEO, Nov 3) Better
Discounts and rebates (gross-to-net deductions; our calculation)1 Q2 about 32% → Q3 about 32.5% Mid-to-high 30% for 2026 (Jul 30, reported) → low end for 2026; approximately the high end in 2027, with Medicare Part D contracting ongoing (CFO, Nov 3, reported) Watch
Cost of sales, % of net sales Reported: Q2 11.0% → Q3 8.8%; excluding Q2’s $10.4M write-down, Q2 was 8.1% (our calculation)2 Mainly higher royalties to Roche as sales grow (Q3 release). The signal reflects the reported ratio; excluding the Q2 write-down, the ratio rose Better
Operating result and free cash flow Operating loss −$56.3M → operating income +$56.0M; free cash flow +$19.1M → +$116.6M (our calculation)3 Profit not expected for full-year 2026 (CFO, Jun 10, reported) → first profitable quarter; may “dip in and out of profitability” (CFO, Nov 3) Better

Sources: Q2 release, Q3 release, 10-Q Q2 2026, 10-Q Q3 2026; management remarks from MarketBeat’s Q3 call transcript and Stock Analysis’s Jun 10 conference transcript (reported).

Unresolved questions: how many patients start and stop each quarter (Madrigal reports only the net number), how much discounts rise in 2027, and whether MAESTRO-NASH OUTCOMES, an event-driven trial, reads out in late 2027 as now expected.

4. Buybacks vs real dilution (5 years)

Last updated Nov 3, 2026. Reflects the equity statements in the 10-K FY2022, 10-K FY2025 and 10-Q Q3 2026, and the offering notes in the 10-Ks for 2021–2024.

Dilution in one line: economic shares outstanding (common plus convertible preferred plus pre-funded warrants; our point-in-time measure, distinct from the company’s weighted-average loss-per-share denominator) rose 53% from Dec 31, 2021 to Sep 30, 2026, about 9.4% a year compounded (our calculation)4. If you owned 1% of Madrigal at the end of 2021, you would own about 0.65% today without buying more (our calculation)5. None of the new shares were offset by buybacks. Our scale: High (over 3% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2021 to Sep 30, 2026FY2022 +7.3%, FY2023 +18.7%, FY2024 +15.2%, FY2025 +3.0%, 9M 2026 +1.3%. Total +53.1% since Dec 31, 2021.0%+20%+40%+60%FY2022: +7.3% in the period; +7.3% since Dec 31, 2021+7.3%FY2022FY2023: +18.7% in the period; +27.4% since Dec 31, 2021+18.7%FY2023FY2024: +15.2% in the period; +46.7% since Dec 31, 2021+15.2%FY2024FY2025: +3.0% in the period; +51.1% since Dec 31, 2021+3.0%FY20259M 2026 (part year): +1.3% in the period; +53.1% since Dec 31, 2021+1.3%9M 2026+53.1%since Dec 31, 2021

Change in the period Total since Dec 31, 2021 Part year

Shares outstanding at period end (all classes): 19.1M on Dec 31, 2021, 29.2M on Sep 30, 2026, +53.1% (our calculation). A bar below zero means the count fell (net buybacks).

Economic shares: common plus Series A and B convertible preferred plus pre-funded warrants (the count Madrigal uses for loss per share), from the author's bridge (10-K and 10-Q equity statements); the preferred and the warrants have no standard XBRL tag.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
9M 2026 (Sep 30, 2026)29.2M+1.3%———
FY2025 (Dec 31, 2025)28.8M+3.0%—$98M10%
FY2024 (Dec 31, 2024)28.0M+15.2%—$80M44%
FY2023 (Dec 31, 2023)24.3M+18.7%—$50M—
FY2022 (Dec 31, 2022)20.5M+7.3%—$32M—
FY2021 (Dec 31, 2021)19.1M——$27M—

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

Madrigal has bought back no stock in the period. The largest source of new shares was sales for cash (common stock, Series B preferred and pre-funded warrants), followed by equity plans (mainly option exercises).

How we calculated this

Share basis: the headline and the bridge count common shares, Series A and B convertible preferred and pre-funded warrants. The preferred converts 1-for-1 into common and the pre-funded warrants carry a $0.0001 exercise price; Madrigal has counted both in its loss-per-share denominator since its Q1 2026 revision (10-Q Q3 2026, note 13). On common plus preferred only (excluding the pre-funded warrants), the count rose 34.2%, about 6.4% a year (our calculation)6. Madrigal has had no stock split in the period, so no split adjustment is needed.

Bridge (millions of shares) 2022 2023 2024 2025 9M 2026 Total
Start of period 19.07 20.47 24.29 27.98 28.82 19.07
Equity plans (option exercises, vested awards) 0.22 0.43 1.03 0.84 0.38 2.90
Share sales for cash: common 0.78 1.35 1.10 – – 3.23
Share sales for cash: Series B preferred 0.40 – – – – 0.40
Share sales for cash: pre-funded warrants – 2.05 1.56 – – 3.61
Acquisitions or note conversions 0 0 0 0 0 0
Buybacks 0 0 0 0 0 0
End of period 20.47 24.29 27.98 28.82 29.20 29.20

Start and end counts are our calculation from the equity statements4 (10-K FY2022, 10-Q Q3 2026). Rows may not add exactly because of rounding.

  • Reported basic weighted-average shares were 29,247,673 in Q3 2026 and 29,142,570 in the first nine months, including the pre-funded warrants and earned performance share units awaiting settlement; Q3 diluted shares were 30,313,137 (10-Q Q3 2026, note 13).

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2022 — — — 1.18M (0.78M common, 0.40M Series B preferred) $218.96 (our calculation)7 $259.1M 10-K FY2022, note 7: 738,900 at-the-market shares for $159.1M gross; 44,444 common and 400,000 preferred at $225 for about $100.0M
2023 — — — 3.39M (1.35M common, 2.05M pre-funded warrants) $154.73 (our calculation)8 $525.2M 10-K FY2023, note 7: Sep–Oct offering, 1,248,098 common shares and 2,048,098 pre-funded warrants for $500.0M gross ($151.69); 98,101 at-the-market shares for $25.2M gross ($256.88; our calculation)8
2024 — — — 2.65M (1.10M common, 1.56M pre-funded warrants) $260.00 (our calculation)9 $690.0M (our calculation)9 10-K FY2024, note 9: 1,096,153 common shares at $260.00 and 1,557,692 pre-funded warrants at $259.9999; net proceeds $574.0M at the initial closing plus $85.9M from the option shares, totalling $659.9M
2025 — — — — — — 10-K FY2025 equity statement
2026 to date (to Sep 30) — — — — — — 10-Q Q3 2026: no sales under the at-the-market agreement

Madrigal sold shares for cash in 2022, 2023 and 2024, mostly in large offerings, and has bought none back. It has sold nothing since the March 2024 offering, and $300.0M remained available under its at-the-market agreement at Sep 30, 2026.

Basis and details
  • Prices are per share. Raised is gross proceeds before commissions and costs; average price is gross proceeds ÷ shares (or pre-funded warrants) sold (our calculation).
  • Madrigal made no buybacks in the period. Not counted as sales for cash: option exercises and other equity-plan issuance. Employee tax-withholding sales by insiders are their own sales, not company buybacks.
  • Madrigal had $300.0M available under its at-the-market agreement with Cowen at Sep 30, 2026 and made no sales under it in 2025 or the first nine months of 2026 (10-Q Q3 2026).
  • For reference, Yahoo Finance reports a closing price of $434.24 on Oct 23, 2026 (historical prices).
Stock-based pay 2022 2023 2024 2025 9M 2026
$M 31.6 49.7 79.9 98.1 108.3
% of revenue (our calculation)10 n/a (no revenue) n/a (no revenue) 44% 10% 10%

Revenue: $180.1M (2024), $958.4M (2025), $1,106.9M (9M 2026). Stock pay from the cash flow statements (10-K FY2023, 10-K FY2025, 10-Q Q3 2026).

5. Profit vs cash (latest FY and TTM)

Last updated Nov 3, 2026. Reflects the 10-K FY2025, the 10-Q Q3 2025 and the 10-Q Q3 2026. Madrigal reports figures under US generally accepted accounting principles (GAAP) only and no adjusted profit measure.

Madrigal reported its first quarterly profit in Q3 2026, but over the last 12 months it still had a net loss and negative free cash flow. Stock pay narrows the gap between the loss and the cash outflow; the cash outflow includes licensing upfronts, and rising receivables and inventory used cash while rising rebate accruals provided it.

$M FY2025 Trailing twelve months (TTM) to Sep 30, 2026 (our calculation)11
Net loss −288.3 −155.5
Adjusted metric Not reported Not reported
Operating cash flow −189.6 −157.0
Capital spending −0.5 −11.6
Free cash flow (our calculation)12 −190.0 −168.7

The following items explain differences between the reported loss and operating cash flow. Grouped by what each means for future profit and cash:

Helps future profit or cash:

  • Working capital used cash: trade receivables −$80.7M and inventory −$37.0M in 2025 (TTM −$114.1M and −$60.5M; our calculation)13: Receivables reflect recognised sales awaiting collection. Inventory remains an asset until sold or written down. Increases in these balances used operating cash.

Hurts future profit or cash:

  • Accrued liabilities, which hold most rebate and other gross-to-net accruals, provided $131.9M of cash in 2025 ($44.1M TTM; our calculation)13. Gross-to-net reserves rose from $99.3M at Dec 31, 2025 to $208.3M at Sep 30, 2026: Rebates reduce product revenue when the related sales are recognised and are paid later; the resulting liability temporarily supports operating cash flow.
  • Stock-based pay added back $98.1M in 2025 ($134.1M TTM; our calculation)13: Not a cash cost, but it is a cost in the loss and it adds shares (see section 4).

One-off / no lasting effect:

  • Licensing upfronts of $255.0M in the TTM period: $120.0M to CSPC (Oct 2025), $50.0M to Pfizer (Dec 2025), $60.0M to Ribocure (Q1 2026; $10.2M of it held as a prepaid asset) and $25.0M to Arrowhead (Q2 2026): The four upfronts were paid within the TTM period through operating cash flow. Madrigal calls them “one-time”, but it signed four in ten months. Our cash path removes them from usual spending. A $4.0M Ribocure milestone paid in Q3 2026 stays in usual spending.
  • Inventory write-downs of $11.1M in the first nine months of 2026, mostly the $10.4M in Q2: a non-cash charge that reduced net income without using cash in the period.
The raw reconciling items
  • Stock-based pay added back $98.1M in 2025 ($134.1M TTM; our calculation)13.
  • Accrued liabilities, which hold most rebate and other gross-to-net accruals, provided $131.9M of cash in 2025 ($44.1M TTM; our calculation)13. Gross-to-net reserves rose from $99.3M at Dec 31, 2025 to $208.3M at Sep 30, 2026 (10-Q Q3 2026, note 4).
  • Working capital used cash: trade receivables −$80.7M and inventory −$37.0M in 2025 (TTM −$114.1M and −$60.5M; our calculation)13.
  • Licensing upfronts are expensed and paid in cash. Payments in the TTM period were $120.0M to CSPC (Oct 2025), $50.0M to Pfizer (Dec 2025), $60.0M to Ribocure (Q1 2026; $49.8M expensed and $10.2M capitalized as a prepaid asset) and $25.0M to Arrowhead (Q2 2026): $255.0M in total. Madrigal calls these “one-time” (10-Q Q3 2026, notes 11 and MD&A).
  • Inventory write-downs of $11.1M in the first nine months of 2026 reduced net income without using cash in the period (10-Q Q3 2026, cash flow statement).

Funding: how long without new money? (our calculation; as of Sep 30, 2026, the latest filed balance sheet)

  • Excluding one-off licensing upfronts, operations generated about $86M of free cash in the last 12 months (our calculation)14; including them, free cash flow was −$169M, against cash, cash equivalents and marketable securities of $961.0M (our calculation)15 and a $350.0M term loan due Jul 17, 2030. Free cash flow was positive in Q2 and Q3 2026 (+$19.1M and +$116.6M; our calculation)3, and the CFO said operating cash flow has been positive “for the last two quarters” (call transcript).
Funding details
  • Run-out: excluding one-off licensing upfronts, and with known items, cash would not fall below zero within 5 years (cash path below): adjusted TTM free cash flow was +$86.4M (our calculation)14. Including the upfronts, cash would fall below zero in Q3 2030, when the term loan is due16. The company’s own total, $961.8M, also includes $0.8M of restricted cash.
  • The company says its cash, cash equivalents and marketable securities “will be sufficient to fund operations past one year” from the issuance of its financial statements, and that its “rate of cash usage will likely increase” (10-Q Q3 2026).
  • Debt: a $350.0M Blue Owl term loan at the three-month secured overnight financing rate (SOFR, an interest-rate benchmark; 1% floor) plus 4.75%, due Jul 17, 2030. No scheduled principal repayment is due within 24 months; interest is payable quarterly. The loan requires at least $100.0M of unrestricted cash at all times, and a change of control is an event of default (10-Q Q3 2026, note 8).
  • Madrigal has no convertible notes.
  • This is based on past cash flow; spending plans can change it.

Extends the runway:

  • The $150.0M of delayed-draw term loans, available at Madrigal’s election until Dec 31, 2027 and undrawn at Sep 30 (see the financing table under the cash path).

Shortens the runway:

  • The $350.0M term loan, due Jul 17, 2030 (a known item in the cash path), and the requirement to keep at least $100.0M of unrestricted cash at all times. No scheduled principal repayment is due within 24 months, and interest is payable quarterly.

Conditional:

  • The further $250.0M incremental facility, which is uncommitted; the $300.0M at-the-market programme with Cowen, unused since 2024; and the licensing milestones (up to $2.0B CSPC, $4.4B Ribocure, $975.0M Arrowhead, $70.0M+ Pfizer), which Madrigal would owe only if future events occur, with no dates disclosed.

Cash path (our calculation; an illustration, not a forecast):

At the past rate and with known items, cash would not fall below zero within 5 years (to Q3 2031), excluding one-off licensing upfronts from usual spending; the company itself says only that its cash will last “past one year” from its financial statements (10-Q Q3 2026), and expects its rate of cash usage to “likely increase”.

Illustration, not a forecast.

Cash path: ending cash by quarter (illustration)Start $961M, Q4 2026 $983M, Q1 2027 $1.00B, Q2 2027 $1.03B, Q3 2027 $1.05B, Q4 2027 $1.07B, Q1 2028 $1.09B, Q2 2028 $1.11B, Q3 2028 $1.13B, Q4 2028 $1.16B, Q1 2029 $1.18B, Q2 2029 $1.20B, Q3 2029 $1.22B, Q4 2029 $1.24B, Q1 2030 $1.26B, Q2 2030 $1.28B, Q3 2030 $956M, Q4 2030 $978M, Q1 2031 $1000M, Q2 2031 $1.02B, Q3 2031 $1.04B.$0M$250M$500M$750M$1.00B$1.25B$1.50BIf the committed financing is drawn: Delayed-draw term loans under the Blue Owl facility, undrawn $150M (Q4 2027)Q3 2031, if drawn: $1.19B2Start: $961MQ4 2026: $983MQ1 2027: $1.00BQ2 2027: $1.03BQ3 2027: $1.05BQ4 2027: $1.07BQ1 2028: $1.09BQ2 2028: $1.11BQ3 2028: $1.13BQ4 2028: $1.16BQ1 2029: $1.18BQ2 2029: $1.20BQ3 2029: $1.22BQ4 2029: $1.24BQ1 2030: $1.26BQ2 2030: $1.28BQ3 2030: $956MQ4 2030: $978MQ1 2031: $1000MQ2 2031: $1.02BQ3 2031: $1.04BStartQ2 2027Q1 2028Q4 2028Q3 2029Q2 2030Q3 2031Q3 2030: known item −$350M (Term loan principal due Jul 17, 2030 (10-Q, note 8))1
  1. 1 · Q3 2030 · Term loan principal due Jul 17 −$350M
  2. 2 · Cash if drawn: $1.19B at Q3 2031

Ending cash (cash, equivalents and marketable securities) Known item If committed financing is drawn

Quarter Starting cash Usual spending Known items Ending cash Sources / notes
Q4 2026 +961.0 +21.6 0.0 +982.6 No share sale or new borrowing after Sep 30 disclosed by Nov 3
Q1 2027 +982.6 +21.6 0.0 +1,004.1
Q2 2027 +1,004.1 +21.6 0.0 +1,025.7
Q3 2027 +1,025.7 +21.6 0.0 +1,047.3
Q4 2027 +1,047.3 +21.6 0.0 +1,068.9 Delayed-draw availability ($150.0M, undrawn) ends Dec 31, 2027
Q1 2028 +1,068.9 +21.6 0.0 +1,090.5
Q2 2028 +1,090.5 +21.6 0.0 +1,112.1
Q3 2028 +1,112.1 +21.6 0.0 +1,133.7
Q4 2028 +1,133.7 +21.6 0.0 +1,155.3
Q1 2029 +1,155.3 +21.6 0.0 +1,176.8
Q2 2029 +1,176.8 +21.6 0.0 +1,198.4
Q3 2029 +1,198.4 +21.6 0.0 +1,220.0
Q4 2029 +1,220.0 +21.6 0.0 +1,241.6
Q1 2030 +1,241.6 +21.6 0.0 +1,263.2
Q2 2030 +1,263.2 +21.6 0.0 +1,284.8
Q3 2030 +1,284.8 +21.6 −350.0 +956.4 Term loan principal due Jul 17, 2030 (10-Q, note 8)
Q4 2030 +956.4 +21.6 0.0 +978.0
Q1 2031 +978.0 +21.6 0.0 +999.5
Q2 2031 +999.5 +21.6 0.0 +1,021.1
Q3 2031 +1,021.1 +21.6 0.0 +1,042.7

Amounts in $M.

Financing that could extend the runway (committed, not yet counted above):

Quarter Financing that could extend the runway Amount Conditions Source
Q4 2027 (availability ends Dec 31, 2027) Delayed-draw term loans under the Blue Owl facility, undrawn +150.0 Available at Madrigal’s election until Dec 31, 2027; undrawn at Sep 30, 2026 10-Q Q3 2026, note 8

At the past rate and with known items, cash would not fall below zero within 5 years (to Q3 2031), excluding one-off licensing upfronts from usual spending; the company itself says only that its cash will last “past one year” from its financial statements (10-Q Q3 2026), and expects its rate of cash usage to “likely increase”. Companies usually raise money well before that; quarters with less than a year of usual spending left would be flagged in the table.

What the cash path shows:

  • Liquidity floor: cash would stay above the loan’s $100.0M minimum-cash requirement throughout, including after the $350.0M term loan is repaid in Q3 2030.
  • Including the $255.0M of upfronts in usual spending, cash would fall below the $100.0M requirement and below zero in Q3 2030, when the loan is due16.
  • Our path assumes flat spending at the past rate.

Known items:

  • Q3 2030: the $350.0M Blue Owl term loan principal, due Jul 17, 2030 (10-Q Q3 2026, note 8).
  • No other disclosed, dated debt maturities, acquisition payments or completed raises after Sep 30.
How we calculated this

Usual spending is TTM free cash flow excluding one-off licensing upfronts: (−$168.7M + $255.0M) ÷ 4 ≈ +$21.6M a quarter (our calculation)14, held flat, under the one-off rule (one-offs above 20% of the absolute TTM free cash flow are removed). Calculations use unrounded amounts (starting cash $960.966M, quarterly usual spending +$21.588M); displayed values are rounded to $0.1M. Starting cash is cash, cash equivalents and marketable securities at Sep 30, 2026 (restricted cash excluded).

  • Excluded from usual spending, as one-off payments ($255.0M in total, all paid in the TTM period through operating cash flow): $120.0M upfront to CSPC for MGL-2086, paid Oct 2025; $50.0M upfront to Pfizer for ervogastat, paid Dec 2025; $60.0M upfront to Ribocure, paid Q1 2026; and $25.0M upfront to Arrowhead for MGL-0795, paid June 2026 (10-Q Q3 2026, note 11 and MD&A).
  • The TTM period that sets usual spending includes a full year of interest on the term loan. It also covers a period of fast sales growth: quarterly free cash flow went from −$171.3M in Q1 2026 to +$19.1M in Q2 and +$116.6M in Q3 2026 (our calculation)3. A flat past rate does not capture that trend.
  • Not included: licensing milestones (up to $2.0B CSPC, $4.4B Ribocure, $975.0M Arrowhead, $70.0M+ Pfizer), which depend on future events and have no disclosed dates.
  • Not included, under the no-double-counting rule: the $305.9M of active pharmaceutical ingredient (API) purchase obligations to be paid through December 2029 (10-Q Q3 2026), loan interest and operating-lease payments. These are recurring operating costs already inside past free cash flow.
  • Capital spending is inside usual spending: $11.6M TTM against $0.5M in 2025. Madrigal has disclosed no capital-spending plan.
  • The undrawn $150.0M delayed-draw loans and the $300.0M at-the-market programme are not completed raises, so they are not added.

Sources: 10-K FY2025, 10-Q Q3 2025 and 10-Q Q3 2026, cash flow statements.

6. Customer and contract exposure

Last updated Nov 3, 2026. Reflects the 10-K FY2025 and the 10-Q Q3 2026.

Five unnamed specialty pharmacies and distributors each account for more than 10% of gross product revenue. In the first nine months of 2026 they took 90% together (our calculation)17.

Customers at 10% or more of gross product revenue (not named in the filings) 2024 2025 9M 2025 9M 2026
Customer A 39% 34% 34% 30%
Customer B 21% 22% 12% 16%
Customer C 14% 15% 23% 18%
Customer D 12% 12% 3% 13%
Customer E Not separately disclosed Not separately disclosed 15% 13%

Madrigal’s sales depend on five unnamed distributors (90% of gross product revenue in the first nine months of 2026 together), a royalty to Roche, and dependence on external manufacturers: Evonik for the active ingredient, UPM as the primary US tablet supplier, and Corden as the primary European and secondary US tablet supplier.

Share of Madrigal's gross product revenue by customer, first nine months of 2026
Customer A: 30% of gross product revenueCustomer A30%Customer B: 16% of gross product revenueCustomer B16%Customer C: 18% of gross product revenueCustomer C18%Customer D: 13% of gross product revenueCustomer D13%Customer E: 13% of gross product revenueCustomer E13%
Show the data
Label Value Unit
Customer A 30 % of gross product revenue
Customer B 16 % of gross product revenue
Customer C 18 % of gross product revenue
Customer D 13 % of gross product revenue
Customer E 13 % of gross product revenue

Chart source18.

Customer, supplier and patent details
  • Customer letters are the company’s labels in each filing and may not refer to the same customer across filings (10-K FY2025, 10-Q Q3 2026). The 9M 2025 shares are as restated in the Q3 2026 10-Q. There were no sales before April 2024.
  • Trade receivables rose from $134.5M at Dec 31, 2025 to $187.4M at Mar 31 and $192.3M at Jun 30 and $227.4M at Sep 30, 2026 (10-Q Q1, 10-Q Q2, 10-Q Q3 2026).
  • Government programmes: Madrigal’s filings don’t give the Medicare or Medicaid share of revenue. Asked about Rezdiffra volume on the Q3 2025 call, the CEO said the company anticipated 50–55% commercial, 30–35% Medicare and about 10% Medicaid and other (transcript, reported); we found no later figure. Its gross-to-net reserves include government rebates and chargebacks (10-Q Q3 2026, note 2, revenue recognition).
  • Roche licence: a tiered single-digit royalty on resmetirom net sales. Milestones of $5.0M (US approval, Mar 2024) and $3.0M (EU approval, Aug 2025) were paid. Under the January 2026 amendment, the royalty is not reduced until certain patent term extensions expire (10-Q, note 11).
  • Supply: Evonik makes the active ingredient under an agreement whose initial term ends Dec 31, 2029, then renews automatically for two-year periods. UPM is the primary supplier of US Rezdiffra tablets under an August 2023 agreement that runs to April 2032, with a required minimum share of annual needs. Corden Pharma is the primary European tablet supplier and a secondary US supplier; its agreement requires binding delivery forecasts, has an initial term ending in 2029 and is expected to renew for successive two-year terms. Obligations for the active ingredient were about $239.4M at Jun 30, 2026, payable through 2029 (10-K FY2025, 10-Q).
  • Legal: a former employee sued in October 2026, alleging whistleblower retaliation after raising internal concerns about “certain Company data and reporting practices.” Madrigal disputes it and says it doesn’t currently expect pending proceedings to have a material adverse effect. It adds that there can be no assurance future developments won’t have a material impact (10-Q Q3 2026, note 11). An allegation, with no finding reported in this filing.
  • Lender: under the Blue Owl financing agreement, a change of control is an event of default (10-K FY2025).
  • Patents listed in the FDA Orange Book (expiry before any extension): 7,452,882 (Sep 12, 2026); 9,266,861, 10,376,517, 11,564,926 and 11,986,481 (Sep 17, 2033); 12,377,104 (Feb 4, 2045) (10-K FY2025). Two further label patents were listed in 2026, expected to give protection into 2045 and 2042 (Q2 release). The FDA published Rezdiffra’s regulatory review period for the term-extension applications on the ’882 and ’861 patents on Jan 27, 2026 (Federal Register). No extension decision has been disclosed.

7. What to watch

Last updated Nov 3, 2026. Reflects the 10-K FY2025, the 10-Q, release and call for Q3 2026, and the Jan 27, 2026 Federal Register notice.

Date Item Source
Nov 5–9, 2026 18 Madrigal abstracts at the AASLD Liver Meeting, including 13 based on real-world use of Rezdiffra Q3 release
Date not announced as of Nov 3, 2026 Q4 and full-year 2026 results and call Madrigal IR events
Date not disclosed USPTO decision on the patent term extension for the ’882 or ’861 patent Federal Register, Jan 27, 2026
Q1 2027 New Medicare Part D contracts take effect; the CFO expects 2027 gross-to-net discounts “plus or minus the high end” of the 2026 range (mid-to-high 30%) Q3 call transcript (reported)
First half of 2027 Planned start of MAESTRO-CSPH, a second Phase 3 outcomes trial in compensated cirrhosis (more than 2,000 patients), subject to regulatory discussions; results expected in the early 2030s, according to management remarks in the call transcript (reported) Q3 release; call transcript
2027 Planned starts of three Phase 2 trials combining resmetirom with ervogastat, MGL-2086 and MGL-0795, following regulatory discussions Q3 call transcript (reported)
Late 2027 MAESTRO-NASH OUTCOMES results in compensated cirrhosis (F4c); a positive result would support an F4c indication and full approval across F2–F4c, the company says Q3 release; call transcript
Dec 31, 2027 End of availability of the $150.0M delayed-draw term loans 10-Q Q3 2026, note 8
Mar 14, 2028 The earliest date (our calculation)19 a generic application with a patent challenge can be filed under five-year new-chemical-entity exclusivity, as the 10-K describes the rule 10-K FY2025 (Hatch-Waxman section)
2028 54-month outcomes data from MAESTRO-NASH, the confirmatory trial for the US accelerated approval in F2–F3 10-K FY2025
Additional dates
Date Item Source
Jul 17, 2030 Maturity of the $350.0M term loan 10-Q Q3 2026, note 8

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 28, 2026$434.24 (Oct 23)$10.0BIncluding convertible preferred and pre-funded warrants: $12.6B$9.5B7.8×7.4×n/mn/m+149%−16%$498M12 months to Jun 30, 2026
Nov 3, 2026$396.32 (Nov 3)$9.2BIncluding convertible preferred and pre-funded warrants: $11.6B$8.6B6.4×6.0×n/mn/m+93%−12%$620M12 months to Sep 30, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 3, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 28, 2026 row: Corrected Oct 31, 2026: market value now uses common shares outstanding (23.1 million on the 10-Q cover page, Jul 27, 2026), our standard basis, instead of 29.07 million shares including convertible preferred and pre-funded warrants; market value $10.0B (was $12.6B), with enterprise value and multiples recalculated. Price and date unchanged. Nov 3, 2026 row: Corrected Nov 4, 2026: the Q3 10-Q, filed the day we updated this page, discloses a former employee's whistleblower-retaliation complaint, filed in October, which Madrigal disputes; we have added it. We also added the range the CEO gave for volume on the Q3 2025 call; the filings don't give the share of revenue. Figures unchanged. Oct 28, 2026 price: the Long View's stated close (Yahoo Finance). Nov 3, 2026 price: official close, Nasdaq.

Notes and calculations

  1. Our gross-to-net proxy = provision related to current-year sales for the period (quarters by differencing year-to-date figures) ÷ (net product revenue + that provision), from the reserve rollforward; it is not necessarily the same as management’s measure (10-Q Q3 2026, note 4). Q2 2026: provision = H1 $341.687M − Q1 $166.774M = $174.913M; $174.913M ÷ ($364.252M + $174.913M) = 32.4%. Q3 2026: provision = nine months $549.431M − H1 $341.687M = $207.744M; $207.744M ÷ ($431.268M + $207.744M) = 32.5%. Nine months: $549.431M ÷ ($1,106.857M + $549.431M) = 33.2%. FY2025, for reference: $245.102M ÷ ($958.403M + $245.102M) = 20.4%. ↩

  2. Cost of sales ÷ net product revenue: Q2 2026 $40.007M ÷ $364.252M = 11.0%; excluding the write-down, ($40.007M − $10.4M) ÷ $364.252M = 8.1%; Q3 2026 $37.815M ÷ $431.268M = 8.8%. ↩

  3. Quarter = cumulative period − prior cumulative period. Q2 2026: operating cash flow −$144.106M − (−$167.435M) = +$23.329M; capital spending −$8.102M − (−$3.849M) = −$4.253M; free cash flow +$19.076M. Q3 2026: operating cash flow −$23.550M − (−$144.106M) = +$120.556M; capital spending −$12.030M − (−$8.102M) = −$3.928M; free cash flow +$116.628M. Q1 2026 free cash flow = −$167.435M − $3.849M = −$171.284M. ↩ ↩2 ↩3

  4. Start (Dec 31, 2021): 17,103,395 common + 1,969,797 Series A preferred = 19,073,192. End (Sep 30, 2026): 23,221,744 common + 2,369,797 preferred + 3,605,790 pre-funded warrants = 29,197,331. Total change = 29,197,331 ÷ 19,073,192 − 1 = 53.1%. Annual rate = (29,197,331 ÷ 19,073,192)^(1 ÷ 4.75) − 1 = 9.4%, where 4.75 years = Dec 31, 2021 to Sep 30, 2026. ↩ ↩2

  5. 1% × 19,073,192 ÷ 29,197,331 = 0.65%. ↩

  6. Common plus preferred: Sep 30, 2026 23,221,744 + 2,369,797 = 25,591,541; 25,591,541 ÷ 19,073,192 − 1 = 34.2%; (25,591,541 ÷ 19,073,192)^(1 ÷ 4.75) − 1 = 6.4% a year. ↩

  7. 2022: ($159.1M at-the-market + $100.0M registered direct) ÷ (738,900 + 44,444 + 400,000 = 1,183,344 shares) = $218.96. ↩

  8. 2023: ($500.0M + $25.2M) ÷ (1,248,098 + 2,048,098 + 98,101 = 3,394,297 securities) = $154.73. At-the-market only: $25.2M ÷ 98,101 = $256.88. ↩ ↩2

  9. 2024: (1,096,153 common + 1,557,692 pre-funded warrants = 2,653,845 securities) × $260.00 = $690.0M gross (the warrants were sold at $0.0001 less); $690.0M ÷ 2,653,845 = $260.00. ↩ ↩2

  10. Stock-based pay ÷ net revenue: $79.880M ÷ $180.133M = 44% (2024); $98.130M ÷ $958.403M = 10% (2025); $108.336M ÷ $1,106.857M = 10% (9M 2026). ↩

  11. TTM = FY2025 − 9M 2025 + 9M 2026. Net loss: −$288.284M − (−$229.709M) + (−$96.888M) = −$155.463M. Operating cash flow: −$189.553M − (−$56.093M) + (−$23.550M) = −$157.010M. Capital spending: −$0.467M − (−$0.857M) + (−$12.030M) = −$11.640M. ↩

  12. Free cash flow = operating cash flow + capital spending (a negative number): FY2025 −$189.553M − $0.467M = −$190.020M; TTM −$157.010M − $11.640M = −$168.650M. ↩

  13. TTM items = FY2025 − 9M 2025 + 9M 2026. Stock-based pay: $98.130M − $72.342M + $108.336M = $134.124M. Accrued liabilities: $131.902M − $220.321M + $132.515M = $44.096M. Trade receivables: −$80.654M − (−$59.463M) + (−$92.923M) = −$114.114M. Inventory: −$36.978M − (−$35.249M) + (−$58.803M) = −$60.532M. ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  14. Adjusted TTM free cash flow = −$168.650M + $255.0M one-off licensing upfronts ($120.0M + $50.0M + $60.0M + $25.0M) = +$86.350M; ÷ 4 = +$21.588M a quarter. $255.0M is 151% of the absolute TTM free cash flow ($168.650M), above the 20% threshold. ↩ ↩2 ↩3

  15. Cash, cash equivalents and marketable securities = $514.642M + $446.324M = $960.966M. On unadjusted TTM free cash outflow, runway = $960.966M ÷ $168.650M = 5.70 years (22.8 quarters). ↩

  16. Unadjusted path, with usual spending = TTM free cash flow −$168.650M ÷ 4 = −$42.163M a quarter: ending cash $960.966M − 15 × $42.163M = $328.5M in Q2 2030, then $328.5M − $42.2M − $350.0M = −$63.6M in Q3 2030, when the term loan falls due (below both the $100.0M minimum-cash requirement and zero). ↩ ↩2

  17. 30% + 16% + 18% + 13% + 13% = 90% of gross product revenue in the first nine months of 2026. ↩

  18. 10-Q Q3 2026. Customer letters are the company’s labels in each filing and may not refer to the same customer across filings. ↩

  19. Approval Mar 14, 2024 + 4 years = Mar 14, 2028 (five-year new-chemical-entity exclusivity, with challenge filings allowed after four years). ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Madrigal Pharmaceuticals: Website (external site)Investor relations (external site)SEC filings (external site)